Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus co-existing prostate cancer: a research study

<p>Abstract</p> <p>Background</p> <p>The aim of the following study is to evaluate the advancement of incidentally diagnosed prostate cancer in specimen after cystoprostatectomies caused by muscle-invasive bladder cancer. Secondly we assessed the survival in patients after radical cystoprostatectomy whose postoperative specimen was characterized by the presence of co-existing prostate cancer or prostate infiltration by urothelial bladder cancer.</p> <p>Methods</p> <p>Between 1993 and 2009 a total of 320 patients with muscle-invasive bladder cancer underwent cystoprostatectomy. The first analyzed group consisted of 52 patients with bladder cancer infiltrating prostate, while the second group consisted of 21 patients with co-existing prostate cancer. In all patients cancer specific survival and progression were analyzed. Average follow up was 75.2 months (range: 0 - 181).</p> <p>Results</p> <p>Cancer-specific survival was significantly shorter in group I (p = 0.03). Neoplastic progression in patients from group I was observed in 42.2% of patients, while in patients from group II in 23.6% of patients (p = 0.04). No statistical difference was observed in the percentage of positive lymph nodes between the groups (p = 0.22). The median Gleason score in patients with co-existing prostate cancer was equal to 5. The stage of prostate cancer pT₂/pT₃was equal to 20 (96%)/1 (4%) patients. 12 (57%) prostate cancers were clinically insignificant. Biochemical recurrence occurred in 2 (9%) patients.</p> <p>Conclusions</p> <p indent="1">1. Incidentally diagnosed prostate cancer in specimen after cystoprostatectomies is frequently clinically insignificant and characterized by low progression.</p> <p indent="1">2. Patients with bladder cancer infiltrating prostate are characterized by higher percentage of progression and death in comparison with patients with co-existing prostate cancer.</p

Strategy for the management of diabetic macular edema: the European Vitreo-Retinal Society macular edema study

Objective. To compare the efficacy of different therapies in the treatment of diabetic macular edema (DME). Design. Nonrandomized, multicenter clinical study. Participants. 86 retina specialists from 29 countries provided clinical information on 2,603 patients with macular edema including 870 patients with DME. Methods. Reported data included the type and number of treatment(s) performed, the pre-and posttreatment visual acuities, and other clinical findings.The results were analyzed by the French INSEE (National Institute of Statistics and Economic Studies). Main Outcome Measures. Mean change of visual acuity and mean number of treatments performed. Results.The change in visual acuity over time in response to each treatment was plotted in second order polynomial regression trend lines. Intravitreal triamcinolone monotherapy resulted in some improvement in vision. Treatmentwith threshold or subthreshold grid laser also resulted in minimal vision gain. Anti-VEGF therapy resulted in more significant visual improvement. Treatment with pars plana vitrectomy and internal limiting membrane (ILM) peeling alone resulted in an improvement in vision greater than that observed with anti-VEGF injection alone. In our DME study, treatment with vitrectomy and ILM peeling alone resulted in the better visual improvement compared to other therapies

Biomolecular quantum resonance in the treatment of dry eye disease

Balancing the composition of tears and, consequently, restoring the homeostasis of ocular surface, is difficult to achieve. This is due to the complex composition of tears, the variety of secretory glands involved, as well as complex and not fully understood interactions affecting the composition, quality, and quantity of tears. The application of Biomolecular Quantum Resonance technology Rexon EyeTM (Resono Ophthalmic, Italy) is based on providing quantum (portions) of high-frequency electromagnetic energy (4–64 MHz) at low power whose interaction with the transport of ions, proteins of cell membranes, and cells changes cell performance. The use of new technology in the treatment of dry eye syndrome combines existing applications of Biomolecular Quantum Resonance such as surgery, treatment of wounds, treatment of bone fractures, as well as treatment pain.Zrównoważenie składu łez, a co za tym idzie – przywrócenie homeostazy powierzchni oka jest trudne do osiągnięcia. Wpływają na to złożoność składu łez, różnorodność gruczołów wydzielniczych, a także skomplikowane i nie do końca poznane interakcje oddziałujące na skład, jakość i ilość łez. Zastosowanie technologii kwantowego rezonansu komórkowego – Biomolecular Quantum Resonance Rexon EyeTM (Resono Ophthalmic, Włochy) – opiera się na dostarczaniu kwantów (porcji) energii elektromagnetycznej wysokich częstotliwości (4–64 MHz) i niskich mocy, które wchodząc w interakcje z transportem jonów, białek błon komórkowych, a także oddziałując na same komórki, zmieniają ich działanie. Zastosowanie nowej technologii w leczeniu zespołu suchego oka dołącza do istniejących zastosowań kwantowego rezonansu komórkowego, takich jak: chirurgia, leczenie ran, leczenie złamań kości, a także leczenie bólu

Badanie elektrofizjologiczne gałki ocznej – Wzrokowe Potencjały Wywołane (WPW)

Wzrokowe Potencjały Wywołane (WPW) stanowią odpowiedź całej drogi wzrokowej na zadziałanie bodźca na siatkówkę. Droga wzrokowa stanowi swojego rodzaju autostradę, po której wywołany przez bodziec sygnał biegnie aż do płata potylicznego w mózgu, gdzie w polu 17 zlokalizowane są ośrodki odpowiedzialne za proces widzenia (Rys. 1a, 1b). Sygnał świetlny zamieniany jest w siatkówce na sygnał elektryczny, który daje informacje, w jakim stopniu „działa” przewodnictwo w obrębie drogi wzrokowej. Wzrokowe Potencjały Wywołane stanowią ważny element diagnostyki okulistycznej, gdyż pozwalają na diagnozowanie i monitorowanie wielu procesów związanych nie tylko z okulistyką, ale i neurologicznymi schorzeniami, takimi jak np. stwardnienie rozsiane (SM) [1, 5]